Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on November 23, 2015. The report discloses a corporate governance event regarding the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of William K. Heiden as a Class I director, effective November 23, 2015. The Board determined that Mr. Heiden is independent under the Company's Corporate Governance Guidelines, SEC requirements, and Nasdaq listing standards. No family relationships or undisclosed material interests were identified.
Compensation and Governance Details
- Role: Class I Director.
- Compensation: Mr. Heiden will receive a prorated annual retainer starting on the effective date, consistent with the Company's non-employee director compensation arrangements described in the 2015 Proxy Statement.
- Equity Grant: Mr. Heiden received an option to purchase 15,500 shares of Common Stock, vesting over three years.
- Agreements: The Company entered into a standard form of indemnification agreement with Mr. Heiden.
Investor Verification Checklist
- Verify the independence status of William K. Heiden against current Nasdaq listing standards.
- Review the 2015 Proxy Statement (filed April 29, 2015) for details on the non-employee director compensation structure.
- Confirm the vesting schedule and exercise terms of the 15,500 share option grant.
- Check for any subsequent filings regarding changes to the Board composition or director resignations.